EOS imaging Announces the Third Acquisition of the EOS® Platform by the Hospital for Special Surgery (HSS) in New York City

Regulatory News:

EOS Imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced the third EOS platform acquisition by New York City’s Hospital for Special Surgery (HSS). HSS installed its first EOS in 2013 for pediatric cases and its second EOS in 2015 for adult cases. The third EOS system will be dedicated to patients suffering from degenerative and deformative spine conditions. It will free-up the second unit to better serve HSS’ large joint orthopedic reconstruction patients.

HSS is nationally ranked #1 in orthopedics by U.S. News & World Report (2015-16) and has been top-ranked for orthopedics for 24 consecutive years.

Marie Meynadier, CEO of EOS imaging, said, "The acquisition of a third EOS system by HSS speaks to the value of our low-dose, 2D/3D imaging platform. We are pleased and honored by this endorsement of our solutions from a worldwide leader in orthopedic care. HSS also uses our online 3D surgical planning software, hipEOS, which allows them to fully capitalize on EOS’ accurate, 3D patient data at each step of the orthopedic care pathway. This is a trend that we expect to spread across our existing and future sites. We are thrilled to expand our relationship with HSS by delivering an additional system so that more of their patients can benefit from safe and accurate imaging that help to improve the hospital’s diagnostic capabilities and outcomes.”

For more information, please visit www.eos-imaging.com.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

About EOS imaging

EOS imaging designs, develops, and markets EOS, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States, Japan, China, and the European Union. The Group posted 2015 revenues of €21.8 million and employs 122 people. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160608006042/en/